Ashland Inc. (ASH) Balance Sheet

The equity compression is concentrated around the 2025Q2 step-down, when total assets fell alongside goodwill, which suggests write-downs and portfolio exits rather than ordinary earnings retention. Retained earnings sit at zero in the latest two quarters after being above $3.0B earlier, a pattern that may indicate a reclassification or a reset of accumulated results that warrants further investigation before drawing conclusions about underlying earning power. The balance sheet has nonetheless stabilized in the last four quarters, which investors should monitor for signs the shrinkage has run its course.

Because gross debt has been essentially flat while equity contracted, the rising D/E ratio appears driven by denominator effects rather than a deliberate increase in financial risk. Debt of roughly $1.5B against $480M of cash implies net debt near $1.0B, a level that may still constrain flexibility if cash flow weakens. Refinancing needs are not disclosed in the supplied data, so the maturity profile should be reviewed before concluding how much pressure this leverage creates.

The cash build coincides with a current ratio that remains well above 2.0, indicating that short-term obligations are comfortably covered by current assets. Cash of $480M relative to total debt of about $1.5B still leaves a material gap, so liquidity appears adequate rather than abundant. Investors should watch whether the rebuild is sustained or reflects timing of working capital and divestiture proceeds.

The sharp goodwill reduction is consistent with impairments or divestitures, and it lowers the risk that future write-downs will again erode equity at the scale seen previously. A stable PPE base implies the manufacturing footprint has been retained, which supports the view of a continuing specialty chemicals operation. Remaining goodwill of about $700M still represents a substantial share of total assets and should be tested against the Life Sciences segment's performance.